The fastest scan of today’s most useful stories.
Massive wildfires are currently raging across France and Spain, forcing over 250,000 people to evacuate as Spain declares its first national emergency for a wildfire and France faces its largest peacetime evacuation. Fueled by searing heat and prolonged dry conditions, these unprecedented blazes are pushing emergency services to their limits and necessitating international aid.
Health workers in eastern Congo have initiated a strike over payment issues at an Ebola treatment center, severely disrupting patient care amidst a rapidly escalating and unprecedented outbreak. This devastating epidemic, already the fastest-growing on record, has tragically claimed over 1,300 lives from nearly 3,000 confirmed cases.
A massive $111 billion merger between Paramount Skydance and Warner Bros. Discovery has been postponed due to significant antitrust concerns raised by a coalition of state attorneys general. Led by California, 12 states secured a temporary restraining order, delaying the deal's closure until at least June 1, 2027, amid allegations of reduced competition in cable and theatrical markets.
Samsung Electronics has secured a colossal five-year contract, valued at over US$200 billion, to produce advanced 2-nanometer and below chips for Broadcom Inc. This monumental deal, extending through 2030, is poised to significantly strengthen both companies' roles in the booming AI infrastructure market and boost South Korea's manufacturing prowess.
The United States is grappling with its worst measles outbreak since 1991, having already recorded 2,318 cases in 2026, surpassing the total for all of 2025. This alarming surge, fueled by widespread outbreaks, threatens the nation's measles-free status and prompts urgent calls from health officials for vaccination, especially with summer travel facilitating potential further spread.
Leveraging AI, Stanford Medicine researchers have identified a naturally occurring molecule that effectively suppresses appetite and reduces body weight, offering a promising alternative to Ozempic without its typical side effects. This novel molecule precisely targets brain neurons in the hypothalamus, demonstrating significant fat loss in animal studies without inducing adverse reactions like nausea or muscle loss.
